circadian rhythm comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Lead coolant temperature would be around 540 °C, giving a high efficiency of 43%, primary heat production of 700 MWt yielding electrical power of 300 MWe. The operational lifespan of the unit could be 60 years. The design was expected to be completed by NIKIET in 2014 for construction between 2016 and 2020. In January 2026, Rosatom reported that BREST-OD-300 remained under construction and that the metal shell of its central reactor cavity had been installed during 2025.
In common with many historians, Peukert noted that the "Hitler myth" of a superhuman Führer who was steadily making Germany into the world's greatest power first began to fall apart with the German defeat at the Battle of Stalingrad as Hitler had staked his personal prestige on a victory on the Volga, repeatedly stating in his radio speeches in the fall of 1942 that he was executing his master plan for victory at Stalingrad. The fact that Hitler's "master-plan" for victory at Stalingrad instead ended with the destruction of the entire German 6th Army, made worse by the fact that it was the hands of the "Asiatic hordes" as Nazi propaganda always called the Red Army, was a terrible blow to Hitler's prestige, but even then the "Hitler myth" continued to exert it power, albeit in a diluted form. Against the traditional view that the "Hitler myth" came "from above", being the work of Joseph Goebbels's Propaganda Ministry, Peukert argued that the "Hitler myth" came just as much "from below" as ordinary people chose to invest their hopes in the "Hitler myth" as a way of rationalizing their passivity in the Third Reich. Another interest for Peukert were the experiences of youth in the Imperial, Weimar and Nazi era.
Ascites is a build-up of fluid in the peritoneal cavity in the abdomen An enlarged spleen in 35–50% of cases Esophageal varices and gastric varices result from collateral circulation in the esophagus and stomach (a process called portacaval anastomosis). When the blood vessels in this circulation become enlarged, they are called varices. Varices are more likely to rupture at this point. Variceal rupture often leads to severe bleeding, which can be fatal. Caput medusae are dilated paraumbilical collateral veins due to portal hypertension. Blood from the portal venous system may be forced through the paraumbilical veins and ultimately to the abdominal wall veins. The created pattern resembles the head of Medusa, hence the name. Cruveilhier-Baumgarten bruit is bruit in the epigastric region (on examination by stethoscope). It is due to extra connections forming between the portal system and the paraumbilical veins.
==== Drugs ==== Dopamine and corticosteroids, commonly given in the hospital setting, can suppress TSH and suppress conversion of T4 to T3. Other drugs such as estrogen, contraceptives, salicylates, and phenytoin can alter the binding of TBG to TH, resulting in different TH concentrations. Additionally, lithium disrupts thyroid function, and thyromimetic endocrine disrupters may downregulate the HPT axis.
Physical and chemical properties of the drug. The physical properties are solid, liquid and gas. The chemical properties are solubility, stability, pH, irritancy, etc. Site of desired action: the action may be localised and approachable or generalised and not approachable. Rate of extent of absorption of the drug from different routes. Effect of digestive juices and the first pass metabolism of drugs. Condition of the patient. In acute situations, in emergency medicine and intensive care medicine, drugs are most often given intravenously. This is the most reliable route, as in acutely ill patients the absorption of substances from the tissues and from the digestive tract can often be unpredictable due to altered blood flow or bowel motility.
Sources: en.wikipedia.org
=== Quantitative analysis === Quantitative approach requires large number of grain analyses within a sample rock in order to represent the overall detrital zircon population statistically (i.e. the total number of analyses should achieve an appropriate level of confidence). Because of the large sample size, secondary ion mass spectrometry (SIMS) and laser ablation-inductively coupled plasma mass spectrometry (LA-ICPMS) are used instead of thermal ionization mass spectrometry (TIMS). In this case, BSE and CL imagery are applied to select the best spot on a zircon grain for acquiring reliable age.
Field and laboratory measurements have shown that reduced nitrogen-containing third-hand smoke compounds can partition from contaminated indoor surfaces into the gas phase and subsequently be taken up by aqueous aerosol particles, creating a particle-phase reservoir that allows THS components to persist and be redistributed within indoor air. Environmental tobacco smoke can oxidize with environmental nitrous acid to create carcinogenic (cancer-causing) tobacco-specific nitrosamines (TSNAs). One TSNA, called 4-(methylnitrosamino)-1-(3-pyridinyl)-1-butanone (also known as nicotine-derived nitrosamine ketone, or NNK), is a potent lung-specific carcinogen ubiquitous in tobacco smoke and smokers' homes, and has been detected on clothing fibers, dust, and in the air. Nitrosamines, along with other tobacco smoke chemicals that are deposited on surfaces or compounds that formed as a result of surface-phase reactions, can be a major source of toxicity, especially for infants. Infants can be particularly adversely affected given their frequent proximity to household surfaces and their propensity to ingest third-hand smoke residue from surfaces and dust. Review articles have suggested that third-hand smoke-type residues can arise not only from conventional tobacco smoking but also from emissions from e-cigarettes, cannabis and certain illicit substances, with the chemical composition, partitioning behaviour and routes of human exposure depending on the source material and indoor environment.
Director General Tim Davie acknowledges there are "grey areas" and says enforcing impartiality is a "difficult balancing act." Disgraced former pop star Gary Glitter is recalled to prison after breaching his licence conditions. Prime Minister Rishi Sunak announces an extra £5bn of government spending for UK defence over the coming two years. 14 March Royal Mail unveils its first design of a new set of ten special stamps, featuring garden flowers and a silhouette of King Charles III. Following a trial at Preston Crown Court, Eleanor Williams is sentenced to eight-and-a-half years in prison after falsely accusing several men of rape and claiming to have been trafficked by an Asian grooming gang. 15 March Chancellor of the Exchequer Jeremy Hunt presents the 2023 United Kingdom budget to the House of Commons, and says that the UK will avoid going into recession in 2023. The UK government commits to invest £20bn over the next 20 years in low-carbon energy projects, focusing on carbon capture and storage. Teachers, junior doctors, civil servants and Tube drivers stage a mass walkout, amid ongoing concerns regarding pay, jobs, pensions and working conditions. 16 March NHS staff in England, including nurses and ambulance staff, are offered a 5% pay rise from April along with a one-off payment of £1,655 to cover backdated pay. The offer does not include doctors, who are on a different contract.
== Bioinformatics tools == Bioinformatics tools exist to assist with interpretation of mass spectra (see de novo peptide sequencing), to compare or analyze protein sequences (see sequence analysis), or search databases using peptide or protein sequences (see BLAST).
In his principal work, Manfred Eigen stated that the E coded by the I chain can be a specific polymerase or an enhancer (or a silencer) of a more general polymerase acting in favour of formation of the successor of nucleotide chain I. Later, he indicated that a general polymerase leads to the death of the system. Moreover, the whole cycle must be closed, so that En must catalyse I1 formation for some integer n > 1.
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.